Recombinant Human LR3 IGF-I

Catalog Number: 8335-G1

DESCRIPTION

Source *E. coli*-derived

MFPAMPLSSLFVN	Human LR3 IGF-I (Gly49-Ala118 (Glu51Arg)) Accession # P05019
N-terminus	C-terminus

N-terminal Sequence Analysis Met-Phe-Pro-Ala-Met-Pro-Leu-Ser-Ser-Leu

Predicted Molecular Mass 9 kDa

SPECIFICATIONS

SDS-PAGE 7 kDa, reducing conditions

Activity Measured in a serum-free cell proliferation assay using MCF−7 human breast cancer cells. Karey, K.P. *et al.* (1988) Cancer Research **48**:4083.
The ED_{50} for this effect is typically 0.3-1.5 ng/mL. IGFBP-3 does not inhibt its activity.

Endotoxin Level <0.01 EU per 1 µg of the protein by the LAL method.

Purity >95%, by SDS-PAGE with silver staining.

Formulation Lyophilized from a 0.2 µm filtered solution in phosphate buffer, pH 7.2 . See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 500 µg/mL in sterile PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA

SDS-PAGE



1 µg/lane of Recombinant Human LR3 IGF-I was resolved with SDS-PAGE under reducing (R) conditions and visualized by silver staining, showing a single band at 7 kDa.

Bioactivity



Recombinant Human LR3 IGF-I (Catalog # 8335-G1) stimulates cell proliferation in a serum-free assay using the MCF-7 human breast cancer cell line. The ED_{50} for this effect is typically 0.3-1.5 ng/mL.

Mass Spectrometry



ESI analysis of Recombinant Human LR3 IGF-I (Catalog # 8335-G1). The peak at 9112 Da corresponds to the calculated molecular mass, 9118 Da.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956

Recombinant Human LR3 IGF-I

Catalog Number: 8335-G1

BACKGROUND

Insulin-like Growth Factor I (IGF-I), also known as Somatomedin C, is the dominant effector of Growth Hormone (GH) and is structurally homologous to Proinsulin. Human IGF-I is synthesized as two precursor isoforms with N- and alternative C-terminal propeptides (1). These isoforms are differentially expressed by various tissues (1). The 7.6 kDa mature IGF-I is identical between isoforms and is generated by proteolytic removal of the N- and C-terminal regions. Mature human IGF-I shares 94% and 96% amino acid (aa) sequence identity with the mouse and rat orthologs, respectively (2). GH stimulates the production of IGF-I in most tissues (3). Hepatocytes produce circulating IGF-I, while local IGF-I is produced by many other tissues in which it has paracrine effects (1). IGF-I induces the proliferation, migration, and differentiation of a wide variety of cell types during development and postnatally (4, 5). IGF-I regulates glucose, fatty acid, and protein metabolism, steroid hormone activity, and cartilage and bone metabolism (6-11). It plays an important role in muscle regeneration and tumor progression (1, 12, 13). IGF-I binds IGF-I R, IGF-II R, and the Insulin Receptor, although its effects are mediated primarily by IGF-I R (14). IGF-I also binds with strong affinity to IGF binding proteins (IGFBPs), which regulate the availability and biological activities of IGF-I (15, 16).

Long R3 IGF-I (LR3 IGF-I) is a 9.2 kDa synthetic analog of IGF-I that is generated by modifying the aa sequence for mature human IGF-I. These modifications include the substitution of an Arg for Glu at position 3 of the mature IGF-1 sequence and the addition of a thirteen aa N-terminal extension, which is derived from methionyl porcine Growth Hormone (17). These aa changes generate a protein that is still capable of binding to IGF-I and Insulin receptors, but shows considerably lower affinity binding to IGFBPs compared to wild-type IGF-I (17, 18). As a result, LR3 IGF-I has an increased half-life and displays increased biological potency compared to IGF-I (17-22).

References:

1. Philippou, A. *et al.* (2007) In Vivo **21**:45.
2. Sandberg-Nordqvist, A.C. *et al.* (1992) Brain Res. Mol. Brain Res. **12**:275.
3. Berryman, D.E. *et al.* (2013) Nat. Rev. Endocrinol. **9**:346.
4. Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. **39**:890.
5. Sadagurski, M. and M.F. White (2013) Endocrinol. Metab. Clin. North Am. **42**:127.
6. Clemmons, D.R. (2006) Curr. Opin. Pharmacol. **6**:620.
7. Bluher, S. *et al.* (2005) Best Pract. Res. Clin. Endocrinol. Metab. **19**:577.
8. Garcia-Segura, L.M. *et al.* (2006) Neuroendocrinology **84**:275.
9. Malemud, C.J. (2007) Clin. Chim. Acta **375**:10.
10. Ling, P.R. *et al.* (1995) Am. J. Clin. Nutr. **61**:116.
11. Sheng, M.H. *et al.* (2014) J. Bone Metab. **21**:41.
12. Samani, A.A. *et al.* (2007) Endocrine Rev. **28**:20.
13. Gallagher, E.J. *et al.* (2010) Endocr. Pract. **16**:864.
14. LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. **3**:302.
15. Denley, A. *et al.* (2005) Cytokine Growth Factor Rev. **16**:421.
16. Duan, C. and Q. Xu (2005) Gen. Comp. Endocrinol. **142**:44.
17. Francis, G.L. *et al.* (1992) J. Mol. Endocrinol. **8**:213.
18. Voorhamme, D. and C.A. Yandell (2006) Mol. Biotechnol. **34**:201.
19. Tomas, F.M. *et al.* (1993) Biochem. J. **291**:781.
20. Tomas, F.M. *et al.* (1996) J. Endocrinol. **150**:77.
21. Tomas, F.M. *et al.* (1997) J. Endocrinol. **155**:377.
22. von der Thüsen, J.H. *et al.* (2011) Am. J. Pathol. **178**:924.

bio-techne
bio-techne.com
Global info@bio-techne.com techsupport@bio-techne.com
North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449
China info.cn@bio-techne.com TEL +86 (21) 52380373
Rest of World bio-techne.com/find-us/distributors TEL +1 612 379 2956